Your session is about to expire
← Back to Search
Immunotherapy for Multiple Myeloma
Study Summary
This trial studies modified T cells to see how well they work in treating MM that has come back or does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have hepatitis B or C and it's currently harming my liver.Your heart's pumping ability is less than 45%.I am between 18 and 74 years old.My multiple myeloma has returned or didn't respond after 3 treatments including a proteasome inhibitor, an immunomodulatory agent, and anti-CD38 therapy.I may need or have recently used systemic steroids, but not inhaled or topical ones.My cancer has spread to my brain or spinal cord.I had a stem cell transplant using my own cells within the last 12 weeks.I have had cancer in the past 3 years, but it may be an exception.I've had anti-BCMA therapy without severe side effects.My multiple myeloma can be measured by specific blood or urine tests.I am not pregnant or breastfeeding, and if I can have children, I agree to use birth control during and for 6 months after treatment.I am mentally capable of understanding and following the study's requirements.My white blood cell count is high enough for treatment.Your bilirubin levels should be within a certain range, unless you have Gilbert's syndrome.Your oxygen level is 92% or lower when breathing regular air.I am willing to undergo a procedure to collect white blood cells.I have had a stem cell transplant from a donor.I've had treatment for multiple myeloma within the last 2 weeks.You have HIV or other conditions that weaken your immune system.I am fully active or restricted in physically strenuous activity but can do light work.Unable to collect at least 500 million CD62L-enriched cells from a blood collection process.You have had a bad reaction to any of the medications used in this study, or you are sensitive to cyclophosphamide or fludarabine.My hemoglobin level is at least 8 g/dL.Your liver enzymes (AST, ALT) should not be more than 2.5 times the normal level.My platelet count is at least 50, without needing a transfusion recently.My kidney function is good enough for the trial, based on recent tests.
- Group 1: Treatment (CART-BCMA/CS1)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the age range for this research include individuals younger than sixty?
"This study is seeking volunteers aged between 18 and 74 years old."
What adverse effects might arise from Treatment (CART-BCMA/CS1) for those receiving it?
"Due to the limited data available, Treatment (CART-BCMA/CS1) received a score of 1 for safety. This is because it is still in its initial phase and there have been no significant findings regarding efficacy or safeguarding protocols."
Is this medical study actively inviting participants?
"According to the clinicaltrial.gov database, this medical trial is currently not recruiting patients as its last update was on July 10th 2023. Despite that fact, 819 other studies are actively searching for participants right now."
What criteria must potential participants meet in order to be involved in this clinical experiment?
"For eligibility in this medical trial, individuals must be diagnosed with multiple myeloma and aged between 18 to 74 years old. Approximately 30 participants are being accepted into the study."
Share this study with friends
Copy Link
Messenger